| Literature DB >> 35756963 |
Yina Wang1,2,3, Xiaonan Liu3,4,5, Bihuan Chen1,2,3, Wei Liu3,5,6, Zhaokuan Guo1,2,3, Xiangyu Liu1,2, Xiaoxi Zhu3,4,5, Jiayu Liu3,5, Jin Zhang3,5, Jing Li3,5, Lei Zhang3,5,6, Yadi Gao3,5, Guanghui Zhang1,2, Yan Wang7, M Iqbal Choudhary7, Shengchao Yang1,2, Huifeng Jiang3,4,5.
Abstract
Scutellarin related drugs have superior therapeutic effects on cerebrovascular and cardiovascular diseases. Here, an optimal biosynthetic pathway for scutellarin was constructed in Yarrowia lipolytica platform due to its excellent metabolic potential. By integrating multi-copies of core genes from different species, the production of scutellarin was increased from 15.11 mg/L to 94.79 mg/L and the ratio of scutellarin to the main by-product was improved about 110-fold in flask condition. Finally, the production of scutellarin was improved 23-fold and reached to 346 mg/L in fed-batch bioreactor, which was the highest reported titer for de novo production of scutellarin in microbes. Our results represent a solid basis for further production of natural products on unconventional yeasts and have a potential of industrial implementation.Entities:
Keywords: Combinatorial gene overexpression; Metabolic engineering; Scutellarin; Yarrowia lipolytica
Year: 2022 PMID: 35756963 PMCID: PMC9184295 DOI: 10.1016/j.synbio.2022.05.009
Source DB: PubMed Journal: Synth Syst Biotechnol ISSN: 2405-805X
Fig. 1Metabolic pathway for scutellarin synthesis from glucose in Abbreviations: PAL, phenylalanine ammonia-lyase; C4H, cinnamate-4-hydroxylase; 4CL, 4-coumaroyl-CoA ligase; CHS, chalcone synthase; CHI, chalcone isomerase; FSII, flavone synthase II; F6H, flavone-6-hydroxylase; ATR2, cytochrome P450 reductase; F7GAT, flavonoid-7-O-glucuronosyltransferase; UDPGDH, UDP-glucose dehydrogenase. Multiple arrows represent multiple enzymatic steps, red genes describe the introduced artificial pathway. In this study, PAL and C4H from A. thaliana or E. breviscapus, 4CL from A. thaliana or E. breviscapus, CHS from H. androsaemum or E. breviscapus, ATR2 from A. thaliana, F6H from E. breviscapus, Scutellaria baicalensis Georgi, Scutellaria barbata D. Don, C. canadensis and C. cardunculus.
Fig. 2Naringenin, apigenin-7-O-glucuronide and scutellarin produced in engineered Error bars represent standard deviation of at least three biological replicates. The “-” and “+” symbols indicate lack or existence of the corresponding genetic modification, respectively. A. HPLC analysis of YL4 fermentation samples and naringenin standard. B. Naringenin production in different combinations of CHS and 4CL in shake-flask fermentation. C. HPLC analysis of the scutellarin standard, apigenin-7-O-glucuronide standard and YL5 samples. D. Scutellarin and apigenin-7-O-glucuronide production with different combinations of PAL and C4H in shake-flask fermentation.
Fig. 3Metabolic engineering to improve the ratio and yield of scutellarin.
A. Schematic illustration of the biosynthetic pathways leading to the production of scutellarin and the byproduct apigenin-7-O-glucuronide. B. Scutellarin and apigenin-7-O-glucuronide production in different species of F6H in shake-flask fermentation. C. Evaluation of scutellarin and apigenin-7-O-glucuronide produced by yeast strains YL17, YL21, YL22, YL23, YL24 and YL25 in shake flask.
Fig. 4Fed-batch fermentation of the engineering strain YL25 in 1.3 L bioreactor. A. Schematic diagram of scutellarin biosynthesis process in YL25 strain. The number after the gene represents the number of copies of the gene. B. Production of scutellarin and apigenin-7-O-glucuronide by strain YL25 in fed-batch fermentation.